New technology is key to better epilepsy treatment

March 22, 2013 in Neuroscience

(Medical Xpress)—University of Adelaide scientists are making a major impact on the understanding and diagnosis of epilepsy, which will lead to individualised treatments for sufferers.

Speaking in the lead up to Purple Day for Awareness (Tuesday 26 March), geneticist Professor Jozef Gecz says advances in DNA sequencing have been a huge leap forward in understanding epilepsy.

This, combined with the use of in laboratory research, will lead to further advances in epilepsy treatment, he says.

However, he cautions that the same technology has also helped to reveal that epilepsy is a far more complex condition than previously thought.

"Scientists used to believe that epilepsy was just one condition, possibly with one main cause. But now we know it is a very complex series of neurological disorders – it is many epilepsies, instead of just one epilepsy, with multiple causes and various symptoms," says Professor Gecz, from the University of Adelaide's School of Paediatrics and Reproductive Health.

Epilepsy is common, with up to 3% of the Australian population experiencing epilepsy at some stage in their lives. Genetic and environmental factors, and trauma, can all play a role in the development of epilepsy. Most (but not all) forms cause sufferers to experience seizures, which vary in severity.

Research in Adelaide has played an important role in the understanding of epilepsy in recent years.

"It's really thanks to the pioneering work of Dr John Mulley (Women's and Children's Hospital and University of Adelaide), who discovered the first gene for idiopathic epilepsy almost 20 years ago. Since then, almost 40 idiopathic epilepsy genes have been discovered, many of them by researchers here in Adelaide," Professor Gecz says.

"There are more than 300 genes known today in which can give rise to some form of epilepsy, in addition to other problems like , autism or psychiatric problems.

"Thanks to genetic sequencing technology, in most cases we are now able to solve the mystery about what kind of epilepsy a patient has, and we can do this very quickly, very accurately, and cost effectively.

"Molecular diagnosis is making a huge impact on treatment – it's really taken off in the last few years, and it has the potential to be even more effectively used in the future. Clinicians can now be guided by genetic information when considering treatment of patients with specific epilepsies."

Professor Gecz and colleagues are currently involved in a major national study of epilepsy, with his lab focusing on the "genetic architecture" of the condition.

Provided by University of Adelaide search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests

Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...

Neuroscience created May 18, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Temporal processing in the olfactory system

The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...

Neuroscience created May 17, 2013 | popularity 4 / 5 (1) | comments 0 | with audio podcast report

Melon focus headband turns to Kickstarter for rollout plans

(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...

Neuroscience created May 17, 2013 | popularity 3.7 / 5 (3) | comments 0 | with audio podcast weblog

Deep brain stimulation: A fix when the drugs don't work

Neurological disorders can have a devastating impact on the lives of sufferers and their families.

Neuroscience created May 17, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Brain makes call on which ear is used for cell phone

If you're a left-brain thinker, chances are you use your right hand to hold your cell phone up to your right ear, according to a newly published study from Henry Ford Hospital in Detroit.

Neuroscience created May 16, 2013 | popularity 2 / 5 (2) | comments 0 | with audio podcast


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.